New data reinforce efficacy and convenience of Novartis Cose

New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis

New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis

pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Iceland , United States , Novartis Cosentyx , Todd Fox , Cosentyx Unoready , Bardur Sigurgeirsson , European Academy Of Dermatology , Anniversary Congress , University Of Iceland , Global Head Of Medical Affairs For Immunology , Twitter , Novartis , Exchange Commission , Novartis Europharm , Novartis Pharmaceuticals Corp , European Academy , Professor Bardur Sigurgeirsson , Psoriasis Area , Severity Index , Global Head , Medical Affairs , Global Assessment , Dermatology Life Quality Index , Self Injection Assessment Questionnaire , Annual Congress , Nonradiographic Axial Spondyloarthritis , Patients Treated With Secukinumab , Primary Results , Placebo Controlled Phase , Subjects With Moderate , Isevere Plaque Psoriasis ,